Major Canadian Study Uncovers Strong Link Between Cannabis Use, Anxiety, and Depression

A groundbreaking study led by researchers at McMaster University has revealed a significant and strengthening association between cannabis use and mental health issues like anxiety and depression among Canadians. Published in The Canadian Journal of Psychiatry on February 26, 2026, the research analyzed data from over 35,000 participants across two national surveys spanning 2012 to 2022, capturing the period before and after cannabis legalization in 2018.

This McMaster-led investigation, spearheaded by Assistant Professor Jillian Halladay from the School of Nursing and the Peter Boris Centre for Addictions Research, underscores a public health challenge that has intensified over the decade. As cannabis becomes more accessible and potent, its links to generalized anxiety disorder (GAD), major depressive episodes (MDE), and suicidality have grown more pronounced, particularly among youth—a demographic central to university campuses across Canada.

Understanding the Research Behind the Headlines

The study drew from Statistics Canada's 2012 Canadian Community Health Survey–Mental Health (CCHS-MH, n=25,113) and the 2022 Mental Health and Access to Care Survey (MHACS, n=9,861), both nationally representative cross-sectional surveys of Canadians aged 15 and older in the provinces. Mental health outcomes were rigorously assessed using the World Health Organization's Composite International Diagnostic Interview (CIDI) for DSM-IV diagnoses of GAD and MDE, alongside measures of suicidality (ideation, plans, or attempts).

Cannabis use frequency was categorized as never, less than monthly, once a week or less, or two or more times per week. Researchers employed robust Poisson regression models, adjusting for confounders like age, sex, race, rurality, income, heavy episodic drinking, and smoking. This approach revealed consistent dose-response relationships: higher frequency of use correlated with elevated risks, with additive interactions showing stronger links in 2022 compared to 2012.

Key Findings: A Dose-Dependent Risk Profile

Between 2012 and 2022, prevalence rates doubled for several metrics: GAD rose from 2.6% to 5.2%, MDE from 4.7% to 7.6%, and past-year cannabis use from 11.4% to 20.7%. Frequent use (2+ times/week) surged from 3.7% to 8.3%, while youth suicidality climbed 44%.

• In 2022, regular cannabis users were 4.5 times more likely to have GAD (vs. 2.3 in 2012), 5.2 times for MDE (vs. 3.0), and 5.4 times for suicidality (vs. 3.0).
• The 'number needed to harm' decreased dramatically, e.g., from 35 to 13 for GAD among frequent users.
• Associations strengthened more among youth (15-24) for MDE and suicidality, and among females for GAD.

These patterns suggest not just correlation but an evolving interplay, potentially fueled by higher-THC products, pandemic stress, and self-medication attempts.Read the full study.

Evolution Over a Decade: Pre- and Post-Legalization Shifts

Legalization in 2018 marked a turning point. While overall suicidality held steady at ~3.5%, youth saw sharp rises alongside doubled frequent use. Prior McMaster research (2002-2012) hinted at emerging links, but post-2018 data shows acceleration. For instance, the Ontario Student Drug Use and Health Survey (2013-2023) found teen psychological distress tripling to 27.4%, with heavy users (40+ times/year) facing 18% higher rates—absent a decade earlier.

Photo by Andy Holmes on Unsplash

Spotlight on Youth and University Students

University-aged Canadians (18-24) are particularly vulnerable, aligning with brain development vulnerabilities up to age 25. The Canadian Postsecondary Education Alcohol and Drug Use Survey (2024-25) reports 42% past-year cannabis use among 23-25-year-olds, with half of postsecondary students using monthly. McMaster's teen study notes nearly half of users cite mental health coping, especially girls. Impacts include lower grades, higher dropout risks, and impaired cognition—critical for academic success.

Canadian universities like McMaster emphasize integrated support via wellness centers, screening, and education on Lower-Risk Cannabis Use Guidelines.

Implications for Canadian Higher Education

As cannabis prevalence climbs—29% past-year nationally in 2023—universities face rising mental health demands.Career advice resources now include substance-mental health intersections. McMaster's Peter Boris Centre exemplifies research-to-practice translation, informing campus policies. Challenges: policy variances (e.g., UVic designated areas, Carleton bans), stigma reduction, and resource strains amid post-pandemic distress surges.

Stakeholders urge routine dual screening: cannabis use in mental health services and vice versa. Government guidelines warn daily use heightens anxiety/depression risks via dopamine disruption.

Expert Voices and Stakeholder Perspectives

"The co-occurrence has strengthened over time," notes Halladay. "Health providers must address both cannabis and mental health together." James MacKillop, Canada Research Chair, highlights youth risks. CAMH echoes: no long-term mental health benefits from cannabis, potential psychosis triggers. Government: avoid under age 25, low-THC products. Universities: Manitoba bans recreational on property; others focus education.

• Health Canada: Dependency, emotional dysregulation risks.
• CAMH: Age-dependent psychosis links.
• Universities Canada: Integrated wellness programs.

Broader Context: National Trends and Comparisons

Post-legalization, daily use rose despite stable/declining youth overall use. CCSA: 40% more users 2017-2023, highest 15-35 males. Yet, postsecondary hazardous use ~25% of monthly users. International: similar youth risks in legalized US states. Canada's unique: high-THC edibles/vapes post-2018.

Photo by engin akyurt on Unsplash

Prevention and Solutions: Actionable Insights

Delay initiation past 25; low-THC (<10%); non-inhaled forms; avoid mixing. Campuses: peer support, apps like Grounded, policy education. Evidence-based: integrated therapy outperforms siloed care. For faculty/students: Rate My Professor for supportive educators; higher-ed jobs in addictions research booming.

• Screen routinely in clinics.
• Update guidelines with potency limits.
• Invest in youth prevention via schools/universities.

Future Outlook and Calls to Action

Ongoing McMaster research tracks post-2022 trends. Needed: longitudinal causation studies, intervention trials. Universities: expand career advice on resilient mental health. Explore university jobs, faculty positions in this field. Engage via Rate My Professor and comments. Proactive steps today safeguard tomorrow's leaders.

Balanced view: while self-medication tempts, evidence favors caution. Consult professionals; prioritize evidence-based wellness.